Thus, forcing a cDC1 phenotype by reprogramming in vivo within the tumor is therapeutically attractive, not only to promote tumor-associated antigen presentation but also to recruit effector T-cells for tumor clearance. The gene discussed is MPPE1; the disease is neoplasm.